Japan approves AstraZeneca-Sanofi drug for prevention of RSV disease in infants [Seeking Alpha]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Seeking Alpha
Sanofi ( NASDAQ: SNY ), has been approved in Japan for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in infants. The medicine is expected to be available for the upcoming 2024/25 RSV season, in line with existing Japanese guidelines, the news release stated. AstraZeneca ( AZN ) and Sanofi ( SNY ) announced an agreement in 2017 to develop and commercialize nirsevimab. AstraZeneca leads development and manufacturing activities as part of the deal, while Sanofi leads commercialization activities and records revenue. The Japan approval is based on three Beyfortus pivotal late-stage clinical trials. Across all clinical endpoints, a single dose of Beyfortus demonstrated consistent efficacy against RSV LRTD extending through five months, the duration of a typical RSV season. Separately, AstraZeneca ( AZN ) has received Japan approval for a combination therapy to treat patients with advanced HR-positive breast cancer. AstraZenec
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia APR Newswire
- Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A [Yahoo! Finance]Yahoo! Finance
- Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia APR Newswire
- Excess Deaths In Japan Hit 115,000 Following 3rd COVID Shot; New Study Explains Why [zero hedge]zero hedge
- Bankruptcy allowed Mallinckrodt to end Acthar royalties, 3rd Circ. rules [Reuters]Reuters
SNY
Analyst Actions
- 2/12/24 - TheStreet
SNY
Sec Filings
- 4/25/24 - Form 6-K
- 4/4/24 - Form F-3ASR
- 4/4/24 - Form S-8
- SNY's page on the SEC website